Foreign-invested Pharmaceutical Companies In China Collectively Take Green Measures
This article was originally published in PharmAsia News
Members of the China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee, such as Johnson & Johnson, Bayer HealthCare and Abbott, are annually increasing investment in emissions reduction and environmental protection in China
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.